What Is Enteroglucagon? Definition and What Research Reports

Plain definition

Enteroglucagon is an umbrella term for the glucagon-like peptide products that are made in the intestine rather than in the pancreas. Both groups of molecules originate from the same gene, proglucagon, but the enzymes present in intestinal enteroendocrine L cells cut that precursor at different points than the enzymes in pancreatic alpha cells, so the intestine releases a different family of fragments. A review of enteroglucagon physiology described these gut-derived products as peptide hormones secreted by L cells of the intestinal mucosa in response to luminal nutrients (PMID 31971745). The word "enteroglucagon" therefore describes a source and an assay category more than a single, precisely defined molecule.

What class of molecule is it, and where does it come from?

Enteroglucagon belongs to the glucagon/secretin superfamily of peptide hormones. All members share a common ancestor sequence and act on class B G-protein-coupled receptors. The proglucagon precursor is a single polypeptide; tissue-specific processing by prohormone convertases determines which fragments are released. The review of enteroglucagon physiology described the intestinal products of proglucagon processing, including glicentin and oxyntomodulin, as the peptides historically grouped under the enteroglucagon label (PMID 31971745).

The cells of origin are enteroendocrine L cells, scattered through the epithelium of the ileum and colon and present in smaller numbers more proximally. These are open-type cells: a narrow apical process reaches the gut lumen and can sense nutrients, while secretory granules release peptide into the underlying tissue and bloodstream. Because L cells are renewed continuously from intestinal stem cells, their number in any given biopsy reflects both stem-cell turnover and the transcription factors that direct progenitor cells toward an endocrine fate.

Related proglucagon products

How the term is used in peptide research

The term entered the literature in the era of radioimmunoassay, when antibodies raised against pancreatic glucagon also bound larger, structurally related fragments circulating after a meal. Investigators called this cross-reacting signal "gut glucagon-like immunoreactivity" or enteroglucagon, because the assay could not say which exact peptide it was measuring. As sequencing and specific immunoassays improved, most papers moved to naming the individual peptides — GLP-1, GLP-2, glicentin, oxyntomodulin — and reserved "enteroglucagon" for three situations:

• Historical citation. Older physiology studies are quoted using the original terminology rather than being retroactively renamed.
• Immunohistochemistry of tissue sections. Pathology and gastroenterology groups often label biopsy sections with an antibody that recognises the shared glucagon-like epitope and report the result as the density of "enteroglucagon cells" per unit of epithelium.
• Teaching and reference material. Review articles use the term as a convenient heading for the intestinal branch of proglucagon processing, as in the physiology review of enteroglucagon (PMID 31971745).

Anyone reading peptide literature should note the practical consequence: a figure labelled "enteroglucagon" in a 1980s endocrinology paper and a figure labelled "enteroglucagon-immunoreactive cells" in a 2020s biopsy study are not measuring the same thing in the same way. The first is a plasma immunoreactivity value; the second is a cell count in tissue.

What the published literature reports

Two strands of published work dominate. The first is descriptive physiology. The review of enteroglucagon physiology summarised where these peptides are produced, what stimulates their release, and the functions attributed to the intestinal proglucagon products, describing them as nutrient-responsive hormones of the gut mucosa (PMID 31971745). That review is a reference synthesis rather than a new experiment, so it reports consensus description rather than novel measurements.

The second strand counts enteroglucagon-containing cells in people with functional bowel disorders. In a 2017 study published in BMC Gastroenterology, researchers examined ileal biopsies from patients with irritable bowel syndrome and from controls, and reported abnormalities in intestinal stem cells, neurogenin 3-positive endocrine progenitor cells and differentiated enteroendocrine cells in the patient group (PMID 28764761). Because neurogenin 3 is the transcription factor that commits an intestinal progenitor to an endocrine lineage, the study framed altered enteroendocrine cell densities — including the cell types that produce glucagon-like intestinal peptides — as a possible downstream consequence of altered progenitor differentiation rather than an isolated finding (PMID 28764761).

Enteroglucagon cells in intervention studies: What Studies Report

A 2022 study in Scandinavian Journal of Gastroenterology looked at whether those cell populations shift after an intervention. Researchers obtained colonic biopsies from patients with irritable bowel syndrome before and after faecal microbiota transplantation and reported changes in the densities of colonic enteroendocrine cells following the procedure (PMID 35156893). The finding is relevant to the enteroglucagon literature because it treats enteroendocrine cell density as a modifiable tissue characteristic that tracks with the luminal environment, rather than a fixed trait of the individual (PMID 35156893).

Read together, these papers describe enteroglucagon primarily as a marker and a physiology concept. None of them evaluated enteroglucagon as an administered compound, and none of the verified literature summarised here reported a dose, an administration schedule, or an adverse-event profile for a product called enteroglucagon. That absence is itself part of the definition: enteroglucagon is a category of endogenous gut peptides identified by antibody cross-reactivity, not a research chemical with an established dosing literature.

Common points of confusion

• Enteroglucagon is not pancreatic glucagon. Same gene, different tissue processing, different fragments, as described in the physiology review (PMID 31971745).
• Enteroglucagon is not a single sequence. Papers using the term may be referring to more than one proglucagon fragment at once.
• "Enteroglucagon cells" is a staining result. In biopsy studies such as the irritable bowel syndrome work, the number reported is a count of immunoreactive cells in tissue (PMID 28764761), not a blood level.
• Modern papers usually prefer specific names. If a study is about incretin or intestinal trophic signalling, it will more often name GLP-1 or GLP-2 directly.

Educational note

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, symptom or treatment decision. Nothing here describes how any substance should be obtained, prepared or administered, and the studies summarised above are reported as published findings, not as recommendations.

References

• Physiology, Enteroglucagon (StatPearls, 2026)
• Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome (BMC Gastroenterology, 2017)
• Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation (Scandinavian Journal of Gastroenterology, 2022)